BioCentury | Feb 15, 2017
Distillery Therapeutics

Other

...postpartum milk ejection and has the compound in Phase II testing for autism and schizophrenia. Trigemina Inc....
BioCentury | Sep 23, 2013
Clinical News

Trigemina preclinical data

...before treatment (p<0.001). Data were presented at the Napa Pain meeting in Napa. This year, Trigemina...
...of oxytocin receptors is also in the Phase II TRIG-05 trial to treat chronic migraine. Trigemina Inc....
BioCentury | Jun 24, 2013
Financial News

Trigemina completes venture financing

...$4.2 million Investors: Aurus Bios; individual investors Note: The financing is a series A-1 round. Trigemina...
BioCentury | Jun 17, 2013
Clinical News

TI-001: Phase II started

...Phase II TRIG-05 trial to evaluate 15-60 IU of intranasal TI-001 in about 240 patients. Trigemina Inc....
BioCentury | Sep 22, 2011
Targets & Mechanisms

Optimism about oxytocin

...everything from psychiatric disorders to sleep apnea," said Daniel Jacobs, founder, chairman and CEO of Trigemina Inc....
...individual investors. Cornett said he is open to seeking venture capital financing in the future. Trigemina...
...Published online Sept. 22, 2011 Companies and Institutions Mentioned Pastorus Pharma LLC , Laramie, Wyo. Trigemina Inc....
BioCentury | Sep 22, 2011
Distillery Therapeutics

Indication: Neurology

...A alleles of OXTR and testing whether pharmacological modulation of OXTR can affect psychological characteristics. Trigemina Inc....
BioCentury | Aug 16, 2010
Clinical News

Intranasal oxytocin: Additional Phase IIa data

...placebo. Trigemina reported similar data from 25 evaluable patients in May (see BioCentury, May 31). Trigemina Inc....
BioCentury | May 31, 2010
Clinical News

Oxytocin: Interim Phase IIa data

...11% for placebo. The trial is enrolling 80 patients who are refractory to available medication. Trigemina Inc....
BioCentury | Feb 15, 2010
Clinical News

Oxytocin: Phase IIa started

...a double-blind, U.S. Phase IIa trial to evaluate intranasal oxytocin vs. placebo in 80 patients. Trigemina Inc....
Items per page:
1 - 9 of 9
BioCentury | Feb 15, 2017
Distillery Therapeutics

Other

...postpartum milk ejection and has the compound in Phase II testing for autism and schizophrenia. Trigemina Inc....
BioCentury | Sep 23, 2013
Clinical News

Trigemina preclinical data

...before treatment (p<0.001). Data were presented at the Napa Pain meeting in Napa. This year, Trigemina...
...of oxytocin receptors is also in the Phase II TRIG-05 trial to treat chronic migraine. Trigemina Inc....
BioCentury | Jun 24, 2013
Financial News

Trigemina completes venture financing

...$4.2 million Investors: Aurus Bios; individual investors Note: The financing is a series A-1 round. Trigemina...
BioCentury | Jun 17, 2013
Clinical News

TI-001: Phase II started

...Phase II TRIG-05 trial to evaluate 15-60 IU of intranasal TI-001 in about 240 patients. Trigemina Inc....
BioCentury | Sep 22, 2011
Targets & Mechanisms

Optimism about oxytocin

...everything from psychiatric disorders to sleep apnea," said Daniel Jacobs, founder, chairman and CEO of Trigemina Inc....
...individual investors. Cornett said he is open to seeking venture capital financing in the future. Trigemina...
...Published online Sept. 22, 2011 Companies and Institutions Mentioned Pastorus Pharma LLC , Laramie, Wyo. Trigemina Inc....
BioCentury | Sep 22, 2011
Distillery Therapeutics

Indication: Neurology

...A alleles of OXTR and testing whether pharmacological modulation of OXTR can affect psychological characteristics. Trigemina Inc....
BioCentury | Aug 16, 2010
Clinical News

Intranasal oxytocin: Additional Phase IIa data

...placebo. Trigemina reported similar data from 25 evaluable patients in May (see BioCentury, May 31). Trigemina Inc....
BioCentury | May 31, 2010
Clinical News

Oxytocin: Interim Phase IIa data

...11% for placebo. The trial is enrolling 80 patients who are refractory to available medication. Trigemina Inc....
BioCentury | Feb 15, 2010
Clinical News

Oxytocin: Phase IIa started

...a double-blind, U.S. Phase IIa trial to evaluate intranasal oxytocin vs. placebo in 80 patients. Trigemina Inc....
Items per page:
1 - 9 of 9